Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.
Saved in:
| Title: | Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy. |
|---|---|
| Authors: | Rose PG; Peter G. Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH; James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Charles W. Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE; Frederick B. Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA; Gillian M. Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; and Paul A. DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI. rosep@ccf.org., Java J; Peter G. Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH; James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Charles W. Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE; Frederick B. Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA; Gillian M. Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; and Paul A. DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI., Whitney CW; Peter G. Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH; James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Charles W. Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE; Frederick B. Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA; Gillian M. Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; and Paul A. DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI., Stehman FB; Peter G. Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH; James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Charles W. Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE; Frederick B. Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA; Gillian M. Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; and Paul A. DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI., Lanciano R; Peter G. Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH; James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Charles W. Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE; Frederick B. Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA; Gillian M. Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; and Paul A. DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI., Thomas GM; Peter G. Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH; James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Charles W. Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE; Frederick B. Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA; Gillian M. Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; and Paul A. DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI., DiSilvestro PA; Peter G. Rose, Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, OH; James Java, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Charles W. Whitney, Christiana Gynecologic Oncology, Apex Medical Center, Newark, DE; Frederick B. Stehman, Mel and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Rachelle Lanciano, Delaware County Regional Cancer Center, Drexel Hill, PA; Gillian M. Thomas, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; and Paul A. DiSilvestro, Women and Infants Hospital, Brown University, Providence, RI. |
| Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2015 Jul 01; Vol. 33 (19), pp. 2136-42. Date of Electronic Publication: 2015 Mar 02. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
